Finance

Beta
Lists
009420:KRX
Hanall Biopharma Co Ltd
₩51,500.00
-2.83%
(-1,500.00) 1D
Jun 12, 3:30:08 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 009420...
Open
₩54,800
High
₩55,600
Low
₩51,100
Mkt. cap
2.69T
Avg. vol.
562.73K
Volume
0.00
52-wk high
₩73,000
52-wk low
₩24,000
EPS
-₩100
Shares outstanding
52.24M
No. of employees
304
Open
₩54,800
High
₩55,600
Low
₩51,100
Mkt. cap
2.69T
Avg. vol.
562.73K
Volume
0.00
52-wk high
₩73,000
52-wk low
₩24,000
EPS
-₩100
Shares outstanding
52.24M
No. of employees
304
News stories
From sources across the web
About Hanall Biopharma Co Ltd
CEOYoon Jae-chun | Seung Kook Park
Employees304
Founded1973
HeadquartersSeoul, Gangnam District, South Korea
SectorPharmaceutical industry
Websitehanall.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
40.68B
40.80B
37.55B
40.03B
Cost of goods sold
18.77B
19.78B
18.91B
18.72B
Cost of revenue
18.77B
19.78B
18.91B
18.72B
Research and development expenses
5.91B
4.77B
3.58B
3.52B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.52B
15.62B
16.79B
16.64B
Operating expense
20.77B
20.68B
21.35B
20.47B
Total operating expenses
39.54B
40.45B
40.26B
39.19B
Operating income
1.15B
348.88M
-2.71B
838.73M
Other non operating income
-245.65M
66.15M
91.23M
566.24M
EBT including unusual items
1.05B
342.71M
-7.16B
570.25M
EBT excluding unusual items
1.05B
324.21M
-2.74B
570.25M
Income tax expense
447.65M
43.75M
-912.20M
295.24M
Effective tax rate
42.78%
12.77%
12.74%
51.77%
Other operating expenses
162.46M
170.57M
159.83M
178.41M
Net income
598.77M
298.96M
-6.25B
275.01M
Net profit margin
1.47%
0.73%
-16.64%
0.69%
Earnings per share
-
-
-
-
Interest and investment income
76.66M
62.64M
52.44M
138.01M
Interest expense
-21.67M
-20.18M
-80.02M
-372.72M
Net interest expenses
54.99M
42.46M
-27.59M
-234.71M
Depreciation and amortization charges
161.32M
136.95M
129.60M
129.07M
EBITDA
2.02B
1.25B
-1.82B
1.67B
Gain or loss from assets sale
169.00K
-18.50M
-4.84M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer